Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

821.34 -4.11 (-0.50%)
Streaming Delayed Price Updated: 12:52 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares
BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares 
Via The Motley Fool
What Is 1 of the Best Pharmaceutical Stocks to Buy Now?
This pharma giant is entering the rapidly expanding market for weight loss drugs. 
Via The Motley Fool
Down 15%, Should You Buy the Dip on Eli Lilly?
Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy. 
Via The Motley Fool
Topics Intellectual Property
Viking Therapeutics: High Risk, High Reward Play
Via MarketBeat
Should You Buy Eli Lilly Stock Before Oct. 30?
Long-term investors don't need to rush to buy Eli Lilly stock. 
Via The Motley Fool
Eli Lilly To Acquire Adverum Biotechnologies
Via Stocktwits
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
The clinical-stage biotech is working on a new type of weight management drug. 
Via The Motley Fool
Eli Lilly And Co. Stock: Gains As $12.47-Per-Share Adverum Biotech Deal Expands Gene Therapy Portfolio
Eli Lilly stock rises as $12.47-per-share Adverum Biotech deal boosts its gene therapy ambitions and expands ophthalmology pipeline. 
Via Talk Markets
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth. 
Via Benzinga
Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections
Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones. 
Via Benzinga
Eli Lilly Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears
Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price cuts in 2025. 
Via Benzinga
Topics Government
2 Things Investors Should Know About Eli Lilly's $5 Billion Investment to Improve Its Drug Production Capacity
Even aggressive tariffs may prove unable to stop this high-flying stock. 
Via The Motley Fool
Topics Government World Trade
Cipla Shares Fall To Biggest Intra-day Lows In Six Months Despite Eli Lilly Deal For Diabetes Drug
Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India 
Via Stocktwits
Sensex, Nifty Poised For A Subdued Opening; HAL, BDL, Mazagon, Cipla, Colgate, Tata Motors, Kaynes Tech Stocks Are In Focus
Midwest to list at 10 a.m. with GMP indicating a premium of ₹111 
Via Stocktwits
Topics World Trade
WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components
The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 
Via Stocktwits
Topics Artificial Intelligence Earnings
2 Vanguard ETFs to Buy With $1,000 and Hold Forever
These exchange-traded funds could be great complementary additions to your portfolio. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
Via MarketBeat
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies
Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests. 
Via Investor's Business Daily
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
 
Via Benzinga
Topics Initial Public Offering
4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)
Via AB Newswire
Weight Loss Drugs Are Quietly Exploding Employer Health Insurance Costs: 'There Is A Quiet Alarm Bell Going Off'
Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending. 
Via Benzinga
Eli Lilly (LLY): 3 Reasons We Love This Stock
Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period. 
Via StockStory
Topics Stocks Supply Chain
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Novo Nordisk Shares Tumble Amid Sweeping Board Overhaul
Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move... 
Via MarketMinute
Topics Economy Government Intellectual Property
Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager
Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager 
Via The Motley Fool
3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report
The rapid growth rates of recent years aren't guaranteed to continue. 
Via The Motley Fool
Topics Intellectual Property
Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains. 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.